ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $56.99 million. The enterprise value is $65.26 million.
Important Dates
The next confirmed earnings date is Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 9.05 million shares outstanding. The number of shares has increased by 13.08% in one year.
| Current Share Class | 9.05M |
| Shares Outstanding | 9.05M |
| Shares Change (YoY) | +13.08% |
| Shares Change (QoQ) | +0.56% |
| Owned by Insiders (%) | 27.94% |
| Owned by Institutions (%) | 14.34% |
| Float | 6.02M |
Valuation Ratios
The trailing PE ratio is 31.40.
| PE Ratio | 31.40 |
| Forward PE | n/a |
| PS Ratio | 1.96 |
| Forward PS | n/a |
| PB Ratio | 1.91 |
| P/TBV Ratio | 1.91 |
| P/FCF Ratio | 32.30 |
| P/OCF Ratio | 22.50 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 13.50, with an EV/FCF ratio of 36.99.
| EV / Earnings | 37.04 |
| EV / Sales | 2.31 |
| EV / EBITDA | 13.50 |
| EV / EBIT | 30.48 |
| EV / FCF | 36.99 |
Financial Position
The company has a current ratio of 3.85, with a Debt / Equity ratio of 0.48.
| Current Ratio | 3.85 |
| Quick Ratio | 1.89 |
| Debt / Equity | 0.48 |
| Debt / EBITDA | 2.67 |
| Debt / FCF | 8.09 |
| Interest Coverage | 4.02 |
Financial Efficiency
Return on equity (ROE) is 6.61% and return on invested capital (ROIC) is 3.21%.
| Return on Equity (ROE) | 6.61% |
| Return on Assets (ROA) | 3.02% |
| Return on Invested Capital (ROIC) | 3.21% |
| Return on Capital Employed (ROCE) | 5.06% |
| Revenue Per Employee | $376,997 |
| Profits Per Employee | $23,490 |
| Employee Count | 75 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 2.22 |
Taxes
In the past 12 months, ImmuCell has paid $11,185 in taxes.
| Income Tax | 11,185 |
| Effective Tax Rate | 0.63% |
Stock Price Statistics
The stock price has increased by +75.49% in the last 52 weeks. The beta is 0.19, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +75.49% |
| 50-Day Moving Average | 6.24 |
| 200-Day Moving Average | 5.88 |
| Relative Strength Index (RSI) | 51.61 |
| Average Volume (20 Days) | 20,655 |
Short Selling Information
The latest short interest is 7,551, so 0.08% of the outstanding shares have been sold short.
| Short Interest | 7,551 |
| Short Previous Month | 10,009 |
| Short % of Shares Out | 0.08% |
| Short % of Float | 0.13% |
| Short Ratio (days to cover) | 0.36 |
Income Statement
In the last 12 months, ImmuCell had revenue of $28.27 million and earned $1.76 million in profits. Earnings per share was $0.20.
| Revenue | 28.27M |
| Gross Profit | 10.99M |
| Operating Income | 2.14M |
| Pretax Income | 1.77M |
| Net Income | 1.76M |
| EBITDA | 4.83M |
| EBIT | 2.14M |
| Earnings Per Share (EPS) | $0.20 |
Full Income StatementBalance Sheet
The company has $6.00 million in cash and $14.27 million in debt, giving a net cash position of -$8.27 million or -$0.91 per share.
| Cash & Cash Equivalents | 6.00M |
| Total Debt | 14.27M |
| Net Cash | -8.27M |
| Net Cash Per Share | -$0.91 |
| Equity (Book Value) | 29.87M |
| Book Value Per Share | 3.30 |
| Working Capital | 12.69M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $2.53 million and capital expenditures -$768,837, giving a free cash flow of $1.76 million.
| Operating Cash Flow | 2.53M |
| Capital Expenditures | -768,837 |
| Free Cash Flow | 1.76M |
| FCF Per Share | $0.20 |
Full Cash Flow StatementMargins
Gross margin is 38.88%, with operating and profit margins of 7.57% and 6.23%.
| Gross Margin | 38.88% |
| Operating Margin | 7.57% |
| Pretax Margin | 6.27% |
| Profit Margin | 6.23% |
| EBITDA Margin | 17.10% |
| EBIT Margin | 7.57% |
| FCF Margin | 6.24% |
Dividends & Yields
ImmuCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.08% |
| Shareholder Yield | -13.08% |
| Earnings Yield | 3.09% |
| FCF Yield | 3.10% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmuCell has an Altman Z-Score of 2.15 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.15 |
| Piotroski F-Score | 8 |
